MiR221/222 in Cancer: Their Role in Tumor Progression and Response to Therapy

Overview

Journal Curr Mol Med

Publisher Bentham Science Publishers

Specialty Molecular Biology

Date 2011 Nov 16

PMID 22082479

Citations 188

Authors

M Garofalo

C Quintavalle

G Romano

C M Croce

G Condorelli

Affiliations

Soon will be listed here.

Abstract

miRNAs are small non-coding RNAs of ~24 nt that can block mRNA translation and/or negatively regulate its stability. There is a large body of evidence that dysregulation of miRNAs is a hallmark of cancer. miRNAs are often aberrantly expressed and their function is linked to the regulation of oncogenes and/or tumor suppressor genes involved in cell signaling pathway. miR-221 and miR-222 are two highly homologous microRNAs, whose upregulation has been recently described in several types of human tumors. miR-221/222 have been considered to act as oncogenes or tumor suppressors, depending on tumor system. Silencing oncomiRs or gene therapy approaches, based on re-expression of miRNAs that are down-regulated in cancer cells, could represent a novel anti-tumor approach for integrated cancer therapy. Here we will review the role of miR-221/222 in cancer progression and their use as prognostic and therapeutic tools in cancer.

Citing Articles

Diagnostic Value of Glycosylated Extracellular Vesicle microRNAs in Gastric Cancer.

Wang S, Ma C, Ren Z, Zhang Y, Hao K, Liu C Cancer Manag Res. 2025; 17:145-160.

PMID: 39881946 PMC: 11776422. DOI: 10.2147/CMAR.S494747.

miRNAs Dysregulated in Human Papillomavirus-Associated Benign Prostatic Lesions and Prostate Cancer.

Salgado-Hernandez S, Martinez-Retamoza L, Ocadiz-Delgado R, Perez-Mora S, Cedeno-Arboleda G, Gomez-Garcia M Cancers (Basel). 2025; 17(1.

PMID: 39796656 PMC: 11718816. DOI: 10.3390/cancers17010026.

DDX3 participates in miRNA biogenesis and RNA interference through translational control of PACT and interaction with AGO2.

Lai M, Yu Y, Chen C, Yu J, Hung H, Chan S FEBS Open Bio. 2024; 15(1):180-195.

PMID: 39543456 PMC: 11705417. DOI: 10.1002/2211-5463.13920.

Analysis of Candidate miRNAs' Expression in Pancreatic Cancer.

Al-Temaimi R, Abdulkarim B, Al-Ali A, John B, Mallik M, Kapila K Cancer Med. 2024; 13(21):e70400.

PMID: 39513319 PMC: 11544394. DOI: 10.1002/cam4.70400.

MicroRNA expression signature in gastrointestinal stromal tumour & their molecular & histological features.

Ghani A, Singh H, Kumar H, Vaiphei K Indian J Med Res. 2024; 160(1):118-127.

PMID: 39382501 PMC: 11463855. DOI: 10.25259/ijmr_2567_22.

References

Calin G, Liu C, Sevignani C, Ferracin M, Felli N, Dumitru C . MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101(32):11755-60. PMC: 511048. DOI: 10.1073/pnas.0404432101. View

Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W . MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010; 10:367. PMC: 2914702. DOI: 10.1186/1471-2407-10-367. View

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C . MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 2010; 30(9):1082-97. PMC: 3342929. DOI: 10.1038/onc.2010.487. View

Pogribny I, Filkowski J, Tryndyak V, Golubov A, Shpyleva S, Kovalchuk O . Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010; 127(8):1785-94. DOI: 10.1002/ijc.25191. View

Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T . Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene. 2005; 25(17):2537-45. DOI: 10.1038/sj.onc.1209283. View

Calin G, Dumitru C, Shimizu M, Bichi R, Zupo S, Noch E . Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002; 99(24):15524-9. PMC: 137750. DOI: 10.1073/pnas.242606799. View

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

Wong T, Liu X, Wong B, Ng R, Yuen A, Wei W . Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res. 2008; 14(9):2588-92. DOI: 10.1158/1078-0432.CCR-07-0666. View

10.

Tran N, McLean T, Zhang X, Zhao C, Thomson J, OBrien C . MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun. 2007; 358(1):12-7. DOI: 10.1016/j.bbrc.2007.03.201. View

11.

Ali S, Coombes R . Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2003; 2(2):101-12. DOI: 10.1038/nrc721. View

12.

Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, Del Basso De Caro M . miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPμ. Oncogene. 2011; 31(7):858-68. PMC: 4299860. DOI: 10.1038/onc.2011.280. View

13.

Terasawa K, Ichimura A, Sato F, Shimizu K, Tsujimoto G . Sustained activation of ERK1/2 by NGF induces microRNA-221 and 222 in PC12 cells. FEBS J. 2009; 276(12):3269-76. DOI: 10.1111/j.1742-4658.2009.07041.x. View

14.

Li D, Sun H . PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc Natl Acad Sci U S A. 1998; 95(26):15406-11. PMC: 28055. DOI: 10.1073/pnas.95.26.15406. View

15.

Miller T, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro C . MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283(44):29897-903. PMC: 2573063. DOI: 10.1074/jbc.M804612200. View

16.

le Sage C, Nagel R, Egan D, Schrier M, Mesman E, Mangiola A . Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007; 26(15):3699-708. PMC: 1949005. DOI: 10.1038/sj.emboj.7601790. View

17.

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V . MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007; 14(3):791-8. DOI: 10.1677/ERC-07-0129. View

18.

Ariazi E, Ariazi J, Cordera F, Jordan V . Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006; 6(3):181-202. View

19.

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

20.

Zhang C, Zhang J, Zhang A, Wang Y, Han L, You Y . PUMA is a novel target of miR-221/222 in human epithelial cancers. Int J Oncol. 2010; 37(6):1621-6. DOI: 10.3892/ijo_00000816. View